Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

A Case-Control Study of Analgesic Use and Ovarian Cancer

Lynn Rosenberg, Julie R. Palmer, R. Sowmya Rao, Patricia F. Coogan, Brian L. Strom, Ann G. Zauber, Paul D. Stolley and Samuel Shapiro
Lynn Rosenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie R. Palmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Sowmya Rao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia F. Coogan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian L. Strom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann G. Zauber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul D. Stolley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Shapiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    Selected factors among cases of epithelial ovarian cancer, cancer controls, and noncancer controls (%)

    Cases (780)Cancer controls (2053)Noncancer controls (2570)
    Age (yr)
    <40192020
    40–49252538
    50–59292821
    60–79272722
    Parity
    0271923
    1–2423735
    3+293839
    Oral contraceptive use (yr)
    0716567
    1–4202221
    5+71110
    Hysterectomy111715
    Age at menopausea
    <45243540
    45–49302926
    50+463634
    Mother or sister with ovarian cancer2<1<1
    • a Among postmenopausal women.

  • Table 2

    Acetaminophen use and NSAID use 1 day or more per week for at least 6 months among 780 cases of epithelial ovarian cancer, 2053 cancer controls, and 2570 noncancer controlsa

    Drug and useCasesCancer controlsORb (95% CI)Noncancer controlsORb (95% CI)
    Acetaminophen
    No7501955Ref.2462Ref.
    Yes28810.9 (0.6–1.4)951.0 (0.6–1.5)
    Duration 5+ yr18431.0 (0.6–1.8)501.1 (0.6–1.9)
    First use 10+ yr ago7250.6 (0.2–1.4)270.8 (0.3–1.8)
    Last use <1 yr ago26760.9 (0.5–1.4)881.0 (0.6–1.5)
    NSAIDs
    No7151833Ref.2278Ref.
    Yes581950.8 (0.6–1.1)2560.7 (0.5–1.0)
    Duration 5+ yr33840.7 (0.4–1.1)1030.7 (0.4–1.2)
    First use 10+ yr ago21690.8 (0.5–1.3)721.0 (0.6–1.6)
    Last use <1 yr ago421500.8 (0.5–1.1)2270.6 (0.4–0.9)
    • a Women whose only use began within the year before admission or whose timing of use was unknown are excluded.

    • b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.

  • Table 3

    Acetaminophen use and NSAID use 4 days or more per week for at least 6 months among 780 cases of epithelial ovarian cancer, 2053 cancer controls, and 2570 noncancer controlsa

    Drug and useCasesCancer controlsORb (95% CI)Noncancer controlsORb (95% CI)
    Acetaminophen
    No7651992Ref.2514Ref.
    Yes14500.7 (0.4–1.3)520.9 (0.5–1.6)
    Duration 5+ yr10240.9 (0.4–1.9)261.2 (0.5–2.6)
    First use 10+ yr ago5160.6 (0.2–1.7)131.1 (0.4–3.2)
    Last use <1 yr ago13440.7 (0.4–1.4)470.9 (0.5–1.7)
    NSAIDs
    No7331870Ref.2338Ref.
    Yes411600.7 (0.5–1.0)2070.7 (0.5–1.0)
    Duration 5+ yr11630.5 (0.2–0.9)810.5 (0.3–0.9)
    First use 10+ yr ago10560.5 (0.2–0.9)530.7 (0.3–1.3)
    Last use <1 yr ago321170.7 (0.5–1.1)1810.6 (0.4–0.9)
    • a Women whose only use began within the year before admission or whose timing of use was unknown are excluded.

    • b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.

  • Table 4

    Aspirin use and nonaspirin NSAID use 4 days or more per week for at least 6 months among 780 cases of epithelial ovarian cancer, 2053 cancer controls, and 2570 noncancer controlsa

    Drug and useCasesCancer controlsORb (95% CI)Noncancer controlsORb (95% CI)
    Aspirin
    No7501938Ref.2430Ref.
    Yes271010.7 (0.4–1.1)1300.8 (0.5–1.2)
    Duration 5+ yr8510.4 (0.2–0.9)670.5 (0.2–1.0)
    Nonaspirin NSAIDs
    No7631971Ref.2465Ref.
    Yes14720.5 (0.3–0.9)880.5 (0.3–0.9)
    Duration 5+ yr3120.4 (0.2–0.9)150.6 (0.2–2.2)
    • a Women whose only use began within the year before admission or whose timing of use was unknown are excluded.

    • b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.

  • Table 5

    Acetaminophen use and NSAID use 1 day or more per week and 4 days or more per week for at least 6 months among 485 cases of metastatic epithelial ovarian cancer and 295 cases of nonmetastatic epithelial ovarian cancera

    UseCasesORb (95% CI)
    Cancer controlsNoncancer controls
    Metastatic ovarian cancer
    Acetaminophen
    1+ days/weekNo466Ref.Ref.
    1+ days/weekYes180.9 (0.5–1.5)1.0 (0.6–1.7)
    4+ days/weekNo477Ref.Ref.
    4+ days/weekYes70.4 (0.2–1.2)0.7 (0.3–1.6)
    NSAIDs
    1+ days/weekNo445Ref.Ref.
    1+ days/weekYes340.7 (0.5–1.0)0.6 (0.4–0.9)
    4+ days/weekNo458Ref.Ref.
    4+ days/weekYes220.5 (0.3–0.8)0.5 (0.3–0.8)
    Nonmetastatic ovarian cancer
    Acetaminophen
    1+ days/weekNo284Ref.Ref.
    1+ days/weekYes100.9 (0.4–1.8)1.0 (0.5–1.9)
    4+ days/weekNo288Ref.Ref.
    4+ days/weekYes71.0 (0.4–2.3)1.3 (0.6–3.0)
    NSAIDs
    1+ days/weekNo270Ref.Ref.
    1+ days/weekYes241.0 (0.6–1.6)0.9 (0.6–1.4)
    4+ days/weekYes275Ref.Ref.
    4+ days/weekYes190.9 (0.6–1.6)0.9 (0.6–1.6)
    • a Women whose only use began within the year before admission are excluded.

    • b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.

PreviousNext
Back to top
September 2000
Volume 9, Issue 9
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Case-Control Study of Analgesic Use and Ovarian Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Case-Control Study of Analgesic Use and Ovarian Cancer
Lynn Rosenberg, Julie R. Palmer, R. Sowmya Rao, Patricia F. Coogan, Brian L. Strom, Ann G. Zauber, Paul D. Stolley and Samuel Shapiro
Cancer Epidemiol Biomarkers Prev September 1 2000 (9) (9) 933-937;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Case-Control Study of Analgesic Use and Ovarian Cancer
Lynn Rosenberg, Julie R. Palmer, R. Sowmya Rao, Patricia F. Coogan, Brian L. Strom, Ann G. Zauber, Paul D. Stolley and Samuel Shapiro
Cancer Epidemiol Biomarkers Prev September 1 2000 (9) (9) 933-937;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Early-Life Risk Factors for Breast Cancer
  • Sugary Drink Consumption and Colorectal Cancer Risk
  • HPV Testing in Self-samples and Urine
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement